SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $29 | $4 | $6 | $9 |
| Short-Term Investments | $81 | $2 | $7 | $12 |
| Receivables | $1 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $4 | $3 | $3 |
| Total Curr. Assets | $113 | $9 | $16 | $24 |
| Property Plant & Equip (Net) | $19 | $20 | $21 | $20 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $51 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $70 | $21 | $22 | $20 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $183 | $30 | $38 | $44 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $3 | $2 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $7 | $7 | $6 | $5 |
| Total Curr. Liab. | $11 | $11 | $10 | $8 |
| LT Debt | $5 | $5 | $6 | $4 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $2 | $2 | $1 | $6 |
| Total NC Liab. | $8 | $7 | $7 | $10 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $6 | $7 | $4 |
| Total Liabilities | $18 | $18 | $17 | $18 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$94 | -$139 | -$129 | -$124 |
| AOCI | $0 | -$0 | -$0 | -$0 |
| Other Equity | $259 | $152 | $151 | $150 |
| Total Equity | $165 | $12 | $21 | $26 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $183 | $30 | $38 | $44 |
| Net Debt | -$23 | $3 | $1 | -$4 |